Fidus Investment Corporation Prices Public Offering of

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Fidus Investment Corporation Prices Public Offering of Common Stock

EVANSTON, Ill., May 27, 2016 (GLOBE NEWSWIRE) -- Fidus Investment Corporation (NASDAQ: FDUS ) (“Fidus” or the “Company”) today announced that it has priced a public offering of 2,500,000 shares of common stock in an underwritten public offering.  The public offering price was set at $15.27 per share and net proceeds from the offering, after deducting underwriting discounts and estimated offering expenses payable by the Company, are expected to be approximately $38.1 million.  Fidus has also granted the underwriters an option, exercisable for 30 days, to purchase up to 375,000 additional shares of common stock to cover over-allotments, if any.

The Company intends to use the net proceeds of this public offering to make investments in lower middle-market companies in accordance with its investment objective and strategies, to repay the outstanding indebtedness under its credit facility, to take advantage of the increase in allowable borrowing capacity under the Small Business Investment Company (“SBIC”) debenture program, and for working capital and general corporate purposes.  The expansion of the Company’s utilization of the SBIC debenture program is subject to approval by the U.S. Small Business Administration.  

Raymond James, Robert W. Baird & Co. Incorporated and Keefe, Bruyette & Woods, A Stifel Company, are joint bookrunning managers for the offering. BB&T Capital Markets, a division of BB&T Securities, LLC and Oppenheimer & Co. Inc. are co-lead managers for the offering. 

The offering is subject to customary closing conditions and is expected to close on June 2, 2016.

The shares will be sold pursuant to a shelf registration statement on Form N-2 that has been filed with, and has been declared effective by, the U.S. Securities and Exchange Commission.  Investors should carefully consider, among other things, the Company’s investment objective and strategies, charges, expenses and the risks related to Fidus and the offering before investing. The final prospectus supplement dated May 27, 2016, including the base prospectus dated May 2, 2016, contains risk factors and other information about Fidus. The offering may be made only by means of a prospectus and a related prospectus supplement, copies of which may be obtained from Raymond James, 880 Carillon Parkway, St. Petersburg, Florida 33716.

This press release does not constitute an offer to sell or the solicitation of an offer to buy the shares in this offering or any other securities nor will there be any sale of the securities referred to in this press release in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.

ABOUT FIDUS INVESTMENT CORPORATION

Fidus Investment Corporation provides customized debt and equity financing solutions to lower middle-market companies, which management generally defines as U.S. based companies with revenues between $10.0 million and $150.0 million. The Company’s investment objective is to provide attractive risk-adjusted returns by generating both current income from debt investments and capital appreciation from equity related investments. Fidus seeks to partner with business owners, management teams and financial sponsors by providing customized financing for change of ownership transactions, recapitalizations, strategic acquisitions, business expansion and other growth initiatives.

Fidus is an externally managed, closed-end, non-diversified management investment company that has elected to be treated as a business development company under the Investment Company Act of 1940, as amended. In addition, for tax purposes, Fidus has elected to be treated as a regulated investment company, or RIC, under Subchapter M of the Internal Revenue Code of 1986, as amended, or the Code. Fidus was formed in February 2011 to continue and expand the business of Fidus Mezzanine Capital, L.P., which commenced operations in May 2007 and is licensed by the U.S. Small Business Administration as a small business investment company.

FORWARD-LOOKING STATEMENTS

This press release may contain certain forward-looking statements which are based upon current expectations and are inherently uncertain. Any such statements, other than statements of historical fact, are likely to be affected by other unknowable future events and conditions, including elements of the future that are or are not under the Company’s control, and that the Company may or may not have considered; accordingly, such statements cannot be guarantees or assurances of any aspect of future performance. Actual developments and results are highly likely to vary materially from these estimates and projections of the future as a result of a number of factors, including those described from time to time in the Company’s filings with the Securities and Exchange Commission. Such statements speak only as of the time when made, and are based on information available to the Company as of the date hereof and are qualified in their entirety by this cautionary statement. The Company undertakes no obligation to update any such statement now or in the future, except as required by applicable law.

                   
Company Contact:                 Investor Relations Contact:
Edward H. Ross                 Jody Burfening
Chief Executive Officer                 LHA
Fidus Investment Corporation                 (212) 838-3777
(847) 859-3940                 jburfening@lhai.com

 

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Johnson & Johnson Unveils Promising PsA Treatment Data

Updated Category News Views 188

A Game-Changer in Psoriatic Arthritis Treatment? Johnson & Johnson just tossed a headline-grabbing bone into the world of psoriatic arthritis with their new ICOTYDE results. For anyone tangled in the chronic web of psoriatic arthritis, hearing about a potential new treatment like ICOTYDE comes with cautious hope. Between stiff joints and rashy skin, sufferers are often...

Continue Reading
NatGold Pulling NATG From MEXC Amid Security Concerns

Updated Category News Views 180

NatGold Digital's sudden decision to yank its NATG token off MEXC Global reeks of regulatory urgency. With the U.S. Treasury clamping down on fund transfers wrapping up MEXC in their action against Russian laundering, NatGold didn't wait for the ink to dry on that order. They’re off the exchange posthaste. A bit of foresight or sheer necessity? Well, it's got the market...

Continue Reading
Off-Broadway Play 'DUST' Raises Autism Support Funds

Updated Category News Views 238

Here's the scoop: an Off-Broadway production just did something many big hitters can't pull off. 'DUST,' a show crafted like a love letter to the American West, managed to rustle up $30,000 for young adults grappled with autism. Partnering with no less than Yale's Cultural Autism Studies and the Ed Asner Family Center, this effort hit the mark in more ways than one. An...

Continue Reading
Blue Owl Tech Faces Lawsuit Post-44% Share Dive

Updated Category News Views 59

The air's thick with tension for investors of Blue Owl Technology Finance Corp. (NYSE:OTF) as they wake up to the news of a securities class action lawsuit that's no small fry. You don’t have to look too far to see why the folks holding the bag might be steamed. We’re talking about a 44% drop in stock price since the merger with Blue Owl Technology Finance Corp....

Continue Reading
Evaluating GLP-1 Telehealth? Key Questions to Consider

Updated Category News Views 206

Navigating the Landscape of GLP-1 Telehealth Providers In the sprawling jungle of telehealth options for GLP-1 care, it's easy to feel like you're drowning in sameness. Picture this: you land on a sleek page promising the moon and stars, but who knows what's behind the curtain? That's where seasoned advice comes in, like a compass in this murky digital forest. Meant, a...

Continue Reading
JOYEE N01 Kicks Off Global Launch with African Orders

Updated Category News Views 169

A New Chapter for JOYEE N01 There's a moment in every company's life when it either steps boldly into the future or stumbles back into obscurity. For FAW Bestune, October 28, 2026, was one of those defining moments. On this day, they launched global mass production of the JOYEE N01 in Yancheng, China. And boy, did they pull out all the stops—you don't see this kind of...

Continue Reading
TCL's Display Future: AI Meets Screens at DTC 2026

Updated Category News Views 22

Exploring New Horizons in Display Technology There's something brewing in Wuhan: a conference that’s shaping up like a tech enthusiast’s dream. This year, it's all about the symbiosis of cutting-edge tech and dazzling visuals as TCL CSOT gears up to unveil advancements at the Global Display Tech-Ecosystem Conference (DTC) 2026. If you're wondering whether this event...

Continue Reading
Pigeon Unveils Green Innovations at CIIE 2026

Updated Category News Views 187

An International Celebration: Cultural Connections at CIIE Babies have a way of bringing the world together. Every culture has its own quirks and traditions, but the love for a newborn is common ground. Pigeon gets that, and they're putting it on full display at the China International Import Expo (CIIE) in Shanghai. It's their fourth run at this rodeo, and they’re not...

Continue Reading
Sensitron's 270VDC SSPCs: A Power System Shake-Up

Updated Category News Views 293

Revolutionizing Power Distribution with Sensitron Some days, the tech world dishes out real game-changers, and looks like November 6, 2026, was one of those days. Sensitron Semiconductor dropped a bombshell with their SPHM/SEHM Series—a brand-new lineup of programmable 16-channel Solid State Power Controllers (SSPCs). Tailored for the grueling demands of 270VDC power...

Continue Reading
FuelCell Faces Class Action Crunch as Deadline Looms

Updated Category News Views 134

FuelCell's Legal Storm: What to Know Now You ever get that feeling when your gut knows it all before you even finish reading the headline? Well, buckle up, because FuelCell Energy, Inc. (NASDAQ:FCEL) is staring down a potential class-action train wreck, and they ain't got much track left to skid on before the deadline hits hard on November 10th, 2026. The Crunchy Details...

Continue Reading

Top 5 Most Recently Viewed Articles

Eos Energy Enterprises Achieves New Heights in Stock Performance

Updated Category News Views 175

Eos Energy Achieves Significant Stock Milestone Eos Energy Enterprises Inc. (NASDAQ: EOSE) has captured the attention of investors and market watchers alike by reaching a 52-week high of $5.43. This remarkable surge reflects the company's strong market momentum and growing investor confidence in its energy storage solutions. Over the past year, EOSE has experienced an...

Continue Reading
NorthWest Copper Achieves New Financing Milestones and Impact

Updated Category News Views 139

NorthWest Copper's Successful Financing Efforts NorthWest Copper Corp. has made significant strides by closing a second tranche of its flow-through financing. This noteworthy announcement highlights the company's commitment to advancing its exploration and development projects. Details of the Financing Tranche In the latest round, NorthWest secured $3.2 million out of the...

Continue Reading
Exceptional Growth: Coffee Holding Co., Inc. Sees Record Results

Updated Category News Views 246

Remarkable Year for Coffee Holding Co., Inc. Coffee Holding Co., Inc. (NASDAQ: JVA) has announced impressive results for its fiscal year ended October 31, 2024. With net sales increasing by 15% compared to the previous fiscal year, the company is celebrating one of its strongest performances in its history. Strong Financial Performance The company reported a notable...

Continue Reading
Akeso's Ivonescimab Shakes Up Lung Cancer Treatment

Updated Category News Views 34

Pioneering Breakthrough in Lung Cancer Treatment How about that for a game-changer in the cancer space? Akeso, Inc. has thrown down the gauntlet with its ivonescimab therapy, making waves in the world of oncology. This isn’t your regular roll-out news; it’s a full-blown contender challenging the big names in cancer treatment, namely PD-1 therapies. The Details: A...

Continue Reading
Unveiling the Premier Travel Rewards Programs for 2025-2026

Updated Category News Views 231

Unveiling the Premier Travel Rewards Programs for 2025-2026 Choice Privileges has emerged as the top hotel rewards program in the latest rankings, while Alaska Airlines Mileage Plan continues to dominate as the leading airline rewards program. These distinctions were unveiled by a prominent publication known for its comprehensive review and analysis of travel loyalty...

Continue Reading